Labcorp Holdings
LH
367.13
-1.75
-0.47%
Labcorp Holdings
US · LH
#790 by market cap
Listed 1970
367.13
-1.75
-0.47%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q4).
- Total institutional ownership fell 0.4 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 100.60% -0.39pp
- Institutions
- 1,312 -2
- As of
- 2026/Q4 vs. prior period
Holder types
Mutual Fund88.13%
Hedge Fund4.44%
Public Company3.57%
Government Pension Fund1.28%
Private Company1.25%
Sovereign Wealth Fund1.04%
Individual/Insider0.38%
Family Office/Trust0.35%
Insurance Company0.26%
Top holders as of 2026-09-30
BlackRock
8.05% · 6.54M sh
Vanguard Capital Management, LLC
7.10% · 5.77M sh
State Street Global Advisors
4.86% · 3.94M sh
Victory Capital Management Inc.
4.83% · 3.92M sh
Vanguard Portfolio Management, LLC
4.46% · 3.62M sh
FMR
4.24% · 3.45M sh
Boston Partners Global Investors, Inc.
3.63% · 2.95M sh
Geode Capital Management, LLC
2.69% · 2.19M sh
Allspring Global Investments, LLC
2.56% · 2.08M sh
Select Equity Group, L.P.
1.88% · 1.52M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 18 buys · 32 sells
| Name | Role | Stake |
|---|---|---|
| Adam Schechter | Chairperson & CEO | 0.13% |
| Glenn Eisenberg | Former Executive VP & Special Advisor to the CEO | 0.05% |
| Brian Caveney | Exec VP, President of Biopharma Laboratory Services & Chief Medical and Scientific Officer | 0.04% |
| Lance Berberian | Former Executive VP & Special Advisor - Strategy | 0.02% |
| Peter Neupert | Independent Director | 0.02% |
| Garheng Albert Kong | Vice Chairman & Lead Independent Director | 0.02% |
| Mark Schroeder | Former Executive VP, President of Diagnostics Laboratories & COO | 0.02% |
| Kerrii Anderson | Independent Director | 0.01% |
| Amy Summy | Executive VP, Chief Marketing Officer & Consumer Health Lead | 0.01% |
| Bryan Vaughn | Executive VP & President of Diagnostics | 0.01% |
| D. Gilliland | Former Independent Director | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-09 | Brian Caveney | Exec VP, President of Biopharma Laboratory Services & Chief Medical and Scientific Officer | Open Market Disposition | -2,000 | $372.04 |
| 2026-11-03 | Megan Bailey | Former Executive VP and President of Central Laboratory Services & International Labcorp | Intent to Sell (Form 144) | -3,035 | $361.16 |
| 2026-11-02 | Bryan Vaughn | Executive VP & President of Diagnostics | Automatic Disposition | -306 | $353.70 |
| 2026-11-01 | Akinbolade Oyegunwa | Executive VP and Chief Information & Technology Officer | Derivative Exercise and Sale | -118 | $355.59 |
| 2026-11-01 | Bryan Vaughn | Executive VP & President of Diagnostics | Derivative Exercise and Sale | -194 | $355.59 |
| 2026-10-31 | Akinbolade Oyegunwa | Executive VP and Chief Information & Technology Officer | Derivative Exercise and Retained | +252 | -- |
| 2026-10-31 | Bryan Vaughn | Executive VP & President of Diagnostics | Derivative Exercise and Retained | +306 | -- |
| 2026-10-29 | Richelle Parham | Independent Director | Open Market Disposition | -1,078 | $361.22 |
| 2026-08-31 | Brian Caveney | Exec VP, President of Biopharma Laboratory Services & Chief Medical and Scientific Officer | Other Derivative Acquisition | +3,000 | -- |
| 2026-08-31 | Akinbolade Oyegunwa | Executive VP and Chief Information & Technology Officer | Other Derivative Acquisition | +750 | -- |
| 2026-08-31 | Jonathan Meltzer | Chief Operating Officer | Other Derivative Acquisition | +900 | -- |
| 2026-08-31 | Bryan Vaughn | Executive VP & President of Diagnostics | Other Derivative Acquisition | +1,500 | -- |
| 2026-08-16 | Kerrii Anderson | Independent Director | Automatic Disposition | -3,000 | $318.02 |
| 2026-08-10 | Adam Schechter | Chairperson & CEO | Automatic Disposition | -4,669 | $320.37 |
| 2026-08-03 | Amy Summy | Executive VP, Chief Marketing Officer & Consumer Health Lead | Open Market Disposition | -924 | $306.74 |
| 2026-08-02 | Peter Wilkinson | Chief Accounting Officer | Open Market Disposition | -82 | $309.22 |
| 2026-08-02 | Peter Wilkinson | Chief Accounting Officer | Derivative Exercise and Sale | -1,338 | $209.25–309.23 |
| 2026-07-01 | Kathryn Kyle | Executive Vice President | Derivative Exercise and Sale | -165 | $283.88–286.19 |
| 2026-07-01 | Kathryn Kyle | Executive Vice President | Intent to Sell (Form 144) | -92 | $286.19 |
| 2026-07-01 | Bryan Vaughn | Executive VP & President of Diagnostics | Derivative Exercise and Sale | -327 | $283.88–286.19 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Labcorp Holdings discussion 0 comments